A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
NCT02614066
Completed
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: UC San Diego-Moores Cancer Center, La Jolla, California +32 locations
Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +431 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
NCT04679012
Recruiting
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, then followed for 52 weeks or until disease progression or discontinuation due to toxicity or death. After completion of the 52... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Mount Sinai- Icahn School of Medicine, New York, New York +3 locations
Conditions: Richter Syndrome, Chronic Lymphocytic Leukemia
Register for Updates
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
NCT01019876
Completed
This study proposes the use of a reduced intensity chemotherapy/radiation therapy regimen followed by stem cell transplantation, as compared to standard ablative chemotherapy regimens associated with stem cell transplantation, in a population of patients with non-malignant diseases (non-cancer). Eligible patients will have a non-malignant disease in one of the following four strata: bone marrow failure syndromes, immunodeficiencies, inborn errors of metabolism, or histiocytoses. Patients will be... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
10/28/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
Register for Updates
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
NCT03586999
Completed
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/28/2024
Locations: City of Hope Cancer Center, Duarte, California +2 locations
Conditions: Peripheral T Cell Lymphoma
Register for Updates
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
NCT04083495
Recruiting
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that carry the CD30 antigen. Once they are att... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina +1 locations
Conditions: Peripheral T Cell Lymphoma
Register for Updates
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
NCT06305299
Recruiting
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
Register for Updates
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
NCT04776850
Withdrawn
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies). PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the body to support blood cell production. PTI... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
10/22/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
Register for Updates
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
NCT01670500
Completed
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, which is cisplatin in this trial, to learn how well it works in treating a specific cancer. "Investigational" means that cisplatin is still being studied for use in this setting and that research doctors are trying to find out more about it-in this case, how effective cisplatin is for treating breast cancer in BRCA mutation carriers. It also means that the FDA has not yet... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: University of Colorado Cancer Center, Aurora, Colorado +14 locations
Conditions: Breast Cancer
Register for Updates
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
NCT05177796
Withdrawn
This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer. Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Register for Updates
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
NCT04714372
Completed
This Phase I open-label dose escalation study is conducted in two stages with a primary endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and related myeloid diseases.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/22/2024
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia
Register for Updates
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
NCT01356290
Recruiting
Patients with relapsed medulloblastoma, ependymoma and ATRT have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly... Read More
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/17/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +21 locations
Conditions: Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent
Register for Updates